Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 122.62 USD -1.9% Market Closed
Market Cap: 152.1B USD
Section:
 

Relative Value

The Relative Value of one GILD stock under the Base Case scenario is 112.87 USD. Compared to the current market price of 122.62 USD, Gilead Sciences Inc is Overvalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GILD Relative Value
Base Case
112.87 USD
Overvaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
1
vs Industry
63
Median 3Y
3.6
Median 5Y
3.3
Industry
7.8
Forward
5.1
More Details
18.8
P/E
P/E
Price to Earnings
18.8
vs History
52
vs Industry
0
Median 3Y
21.6
Median 5Y
20
Industry
24.4
Forward
14.8
More Details
15.8
P/OCF
P/OCF
Price to OCF
15.8
vs History
1
vs Industry
12
Median 3Y
11
Median 5Y
10.1
Industry
21.4
More Details
15.8
P/FCFE
P/FCFE
Price to FCFE
15.8
vs History
9
vs Industry
11
Median 3Y
13.5
Median 5Y
12.6
Industry
23.2
More Details
7.1
P/B
P/B
Price to Book Value
7.1
vs History
9
vs Industry
14
Median 3Y
4.8
Median 5Y
4.3
Industry
3.3
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
12
vs Industry
50
Median 3Y
4.2
Median 5Y
3.8
Industry
8.4
Forward
4.8
More Details
6.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.2
vs History
12
vs Industry
50
Median 3Y
5.4
Median 5Y
4.9
Industry
10.3
More Details
12.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.6
vs History
1
vs Industry
11
Median 3Y
8.8
Median 5Y
8.2
Industry
6.5
Forward
9.7
More Details
12.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.6
vs History
12
vs Industry
9
Median 3Y
11.1
Median 5Y
9.9
Industry
7
Forward
10.6
More Details
14.8
EV/OCF
EV/OCF
Enterprise Value to OCF
14.8
vs History
9
vs Industry
11
Median 3Y
12.8
Median 5Y
12
Industry
7.9
More Details
14.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.8
vs History
17
vs Industry
9
Median 3Y
13.8
Median 5Y
12.6
Industry
6.2
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
12
vs Industry
39
Median 3Y
2.1
Median 5Y
1.9
Industry
5.5
More Details

Multiples Across Competitors

GILD Competitors Multiples
Gilead Sciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Gilead Sciences Inc
NASDAQ:GILD
152.3B USD 5.2 18.8 12.6 12.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 059 881.3 -161 881.6 -196 575.9 -194 332.7
US
Abbvie Inc
NYSE:ABBV
404.2B USD 6.8 172.2 16.6 23.6
US
Amgen Inc
NASDAQ:AMGN
183B USD 5.1 26.1 18.7 18.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 9.9 31.6 23.2 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.4 -527.8 -574.7 -559.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.1B USD 5.3 16.6 15.8 17.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.9B USD 24.8 -191 -478 -328.1
AU
CSL Ltd
ASX:CSL
88.9B AUD 3.8 19.6 13.1 16.4
NL
argenx SE
XBRU:ARGX
48.2B EUR 15.6 36.7 63.6 65.4
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/S: 3 096 549.6
5.2
4%
1.3
FR
Pharnext SCA
OTC:PNEXF
34 059 881.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 068.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
5%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.8
44%
0.6
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.6
46%
0.3
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/E: 45.9
18.8
191%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 881.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.1
44%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -191 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
11%
1.8
NL
argenx SE
XBRU:ARGX
36.7
37%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBITDA: 23.4
12.6
7%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 575.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.7
10%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -478 N/A N/A
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
NL
argenx SE
XBRU:ARGX
63.6
769%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBIT: 25.5
12.6
13%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 332.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.7
19%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -328.1 N/A N/A
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
NL
argenx SE
XBRU:ARGX
65.4
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
GILD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GILD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GILD stock valuation using valuation multiples.
Wall Street Estimates
GILD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GILD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.